# Study of ORIC-101 in Combination With Anticancer Therapy

> **NCT03928314** · PHASE1 · TERMINATED · sponsor: **ORIC Pharmaceuticals** · enrollment: 83 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** ORIC-101
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT03928314
- **Lead sponsor:** ORIC Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-02
- **Primary completion:** 2022-09-22
- **Final completion:** 2023-12-04
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** IND Withdrawn
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03928314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03928314, "Study of ORIC-101 in Combination With Anticancer Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03928314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*